Asia Pacific Veterinary Vaccine Market: Market Size & Forecast 2026

The Asia Pacific veterinary vaccine market covers biological products used to immunize farm animals, poultry, and companion animals against viral, bacterial, and parasitic diseases. Valued at approximately $4.5 billion in 2025, the market is expanding at a compound annual growth rate of around 1.2%. While the growth rate is moderate, the region remains one of the largest veterinary vaccine markets globally due to its vast livestock and poultry populations.

• •Market size in 2025: approximately $4.5 billion
• •Forecast CAGR through 2030-2035: roughly 1.1% to 1.3%
• •Major demand originates from China, India, Japan, Australia, and Southeast Asia

Rising demand for animal protein, including meat, milk, and eggs, is a key driver as commercial livestock and poultry operations scale up across Asia Pacific. Increasing pet ownership in urban centers, along with greater awareness of preventive animal healthcare, is also expanding the companion animal vaccine segment. Additionally, recurring outbreaks of diseases such as foot-and-mouth disease, avian influenza, classical swine fever, and lumpy skin disease are pushing governments and producers to adopt vaccination as a primary control measure.

• •Growing consumption of animal protein and intensification of livestock farming
• •Rising pet ownership and expenditure on companion animal health in cities
• •Government-led disease control programs targeting foot-and-mouth disease, avian influenza, and swine fevers

The market can be segmented by vaccine type (live attenuated, inactivated, recombinant, and others), animal type (livestock, poultry, companion animals, and aquaculture), and disease indication. Livestock and poultry vaccines account for the majority of revenue, given the scale of farming activities, while companion animal vaccines are growing faster from a smaller base. China and India represent the largest country markets, supported by huge herd sizes, while Japan, Australia, and South Korea are notable for higher-value companion animal vaccine sales.

• •Livestock and poultry vaccines dominate by volume and value
• •Companion animal vaccines are the fastest-growing sub-segment in developed APAC markets
• •Aquaculture vaccines are an emerging niche in countries with large fish and shrimp farming industries

What are the recent trends and outlook?

Key trends include a gradual shift from conventional live and inactivated vaccines toward recombinant, subunit, and mRNA-based platforms, particularly for swine and poultry diseases. Digital tools and improved cold chain logistics are helping extend vaccine reach into remote rural areas. Looking ahead, the market is expected to continue its steady expansion toward $5 billion by around 2035, supported by food security policies, zoonotic disease preparedness, and rising companion animal healthcare spending.

• •Adoption of next-generation vaccine technologies such as recombinant and vectored vaccines
• •Expansion of veterinary cold chain infrastructure in emerging Asian markets
• •Long-term outlook points to continued low-single-digit growth driven by population, protein demand, and disease control programs